Literature DB >> 6872462

Effects of indomethacin on the guinea-pig pulmonary response to intravenous leukotrienes C4 and D4.

A G Leitch, K F Austen, E J Corey, J M Drazen.   

Abstract

We measured pulmonary conductance (GL), dynamic compliance (Cdyn.), and arterial pressure in chloralose-urethane anaesthetized guinea pigs for 30 min after intravenous infusion of either leukotriene (LT) C4 (1 microgram/kg) or LTD4 (0.5 microgram/kg) to control or indomethacin-pretreated (30 mg/kg) animals. LT infusion to control animals caused decrements in GL, which were maximal at 30 s and persisted for 7.5 min (LTD4) and 15 min (LTC4), decrements in Cdyn., which were maximal at 30 s and persisted for 30 min, and hypotension. Indomethacin treatment before LT infusion significantly altered the changes in GL by reducing the early (less than 1 min) response and potentiating the later (3-5 min) response, significantly reduced the fall in Cdyn. at all time points, resulting in a change in the GL/Cdyn. ratio to 1.0 and prolonged the hypotensive response. We conclude that cyclo-oxygenase products are responsible for the early (less than 1 min) pulmonary response to LT infusion and modulate the later (3-5 min) response but do not cause hypotension. With cyclo-oxygenase inhibition, the significant primary activity of LT is possibly less preferentially directed to contractile tissues associated with small airways.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6872462     DOI: 10.1042/cs0650281

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  2 in total

1.  The role of arachidonic acid metabolites in local and systemic inflammatory processes.

Authors:  K F Austen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  The pharmacological evaluation of LY 170680, a novel leukotriene D4 and E4 antagonist in the guinea-pig.

Authors:  J R Boot; A Bond; R Gooderham; A O'Brien; M Parsons; K H Thomas
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.